Updated Data Matrix Available

Market Value | Market Volume | Epidemiology | Clinical Trials | Patent Landscape | Regulatory Approvals | COVID-19 Impact Analysis

Global Noninvasive Prenatal Testing Market $8.1 Billion by 2027

The global market for noninvasive prenatal testing estimated to reach $8.1 billion by 2027, expanding at a double-digit CAGR of 18.5% over the forecast period, driven by increasing demand for screening birth defects, and inherited diseases as well as wider availability of tests worldwide.

  • In addition, the technological advancements, high incidence rate of babies born with Down syndrome, rising average maternal age, and increasing demand for early and non-invasive fetal testing procedures worldwide to drive noninvasive prenatal testing market growth during the forecast period.
Global Noninvasive Prenatal Testing Market

Non-invasive prenatal testing (NIPT) is a non-invasive technique used to test a fetus for a range of genetic conditions and variations using a blood sample taken from the pregnant woman.

  • NIPT using cell-free fetal DNA (cffDNA) circulating in maternal blood can detect common fetal trisomies, such as Down syndrome, fetal Rhesus D status, sex chromosome disorders, and fetal sex. 
    • It is more accurate than other noninvasive prenatal screening tests for Down’s, Edwards’ and Patau’s syndromes, including other combined tests. 
  • There has been exponential growth in the uptake of NIPT to detect fetal aneuploidy with high accuracy post clinical validation studies. 
    • Depending on the health-care setting, different scenarios for NIPT-based screening for common autosomal aneuploidies are possible.
Noninvasive Prenatal Testing (NIPT) Market

The global noninvasive prenatal testing market report estimates the market size ($million 2017 to 2027), number of tests performed, market share, growth trends and forecast (CAGR% 2021 to 2027).

The global market for noninvasive prenatal testing segmented by test (BambniTest, Harmony test, informaSeq Prenatal test, MaterniT21 PLUS, Non-invasive Fetal Trisomy test, Panorama test, PrenaTest, verifi test, VisibiliT test, etc.), and geography.

  • The non-invasive Fetal Trisomy (NIFTY) test developed by BGI Diagnostics and MaterniT21 PLUS tests dominated the number of NIPT testes performed worldwide.
  • The MaterniT21 PLUS test introduced by Sequenom, Inc. for detecting fetal chromosomal aneuploidies in pregnant women accounted for the largest share of total NIPT market.
    • In 2011, the test was introduced to detection of trisomy 21. With the introduction of enhanced sequencing series for MaterniT21 PLUS, can also detect 22q deletion syndrome (DiGeorge), 5p (Cri-du-chat syndrome), 15q, 1p, trisomy 16, and trisomy 22 in addition to trisomies (21, 18, 13) and sex chromosome aneuploidies (X and Y).
  • On the other hand, the VisibiliT test forecast to register the fastest growth rate throughout the forecast period, driven by low base value for test, followed by BambniTest.

The global NIPT market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.

  • NIPT is currently marketed in the United States by four commercial providers (Sequenom, Natera, Verinata, and Ariosa), in Europe by LifeCodexx, and in China by two companies (Berry Genomics and BGI).
    • The availability of NIPT is already leading to a considerable reduction of invasive procedures in the USA, both as a result of women choosing NIPT over direct access to invasive procedures and of the lower false positive rate of NIPT as compared with other first-tier tests. 
      • NIPT was introduced in the United States and Western Europe in late 2011, and tests are rapidly becoming available in the Middle East, South America, South and Southeast Asia, and Africa.
        • Noninvasive prenatal genetic testing is becoming available in low- and middle-income countries, however practical and ethical challenges remains. 

The global noninvasive prenatal tests market research report also provides detailed market landscape and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent acquisitions and alliances. 

Major competitors operating in the global NIPT market and included in this report are Berry Genomics, BGI Group (BGI Diagnostics), Illumina, Inc., Laboratory Corporation of America Holdings (LabCorp/ Sequenom, Inc.), LifeCodexx AG, Natera, Inc., and Roche Holding AG (Ariosa Diagnostics, Inc.).

  • Test
    • BambniTest
    • Harmony Test
    • informaSeq Prenatal Test
    • MaterniT21 PLUS Test
    • Non-invasive Fetal Trisomy (NIFTY) Test
    • Panorama Test
    • PrenaTest
    • Verifi Test
    • VisibiliT Test
    • Others
  • Geography
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Rest of the World
  • Company Profiles
    • Berry Genomics Co., Ltd.
    • BGI Group (BGI Diagnostics)
    • Illumina, Inc.
    • Laboratory Corporation of America Holdings (LabCorp/ Sequenom, Inc.)
    • LifeCodexx AG
    • Natera, Inc.
    • Roche Holding AG (Ariosa Diagnostics, Inc.)

To request Table of Contents and Sample Pages of this report visit:

Related publications:

    Request ToC/Sample information for this market analysis

    Full Name*

    Company Email*

    Phone Number* [Please add country code]



    Secure Online Payment

    iHealthcareAnalyst, Inc.

    Contact Address

    US Office: 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043, United States
    Phone: +1 (314) 315-4764
    India Office: 5, Shilpa Chambers, Opp. J. M. Road, Shivajinager, Pune 411005, India
    Phone: +91 (20) 25898524
    Email: [email protected]